Methyldopa (versus unexposed) updated on 03-11-2025

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17246
R72171		 Vaclavik, 2024 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 2.11 [2.03;2.20] -/3,979   -/252,856 - 3,979
ref
S14335
R56710		 Hoeltzenbein, 2017 C-section at least 1st trimester excluded prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 2.78 [2.02;3.82] C
excluded (exposition period) 		142/239   165/478 307 239
ref
S14281
R56177		 Fidler, 1983 Elective caesarean section during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 2.54 [1.13;5.71] C 16/50   15/96 31 50
ref
Total 2 studies 2.11 [2.03;2.20] 31 4,029
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik, 2024Vaclavik, 2024 2.11[2.03; 2.20]-3,979100%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Fidler, 1983Fidler, 1983 2.54[1.13; 5.71]31500%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.11[2.03; 2.20]314,0290.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.11[2.03; 2.20]314,0290%NAVaclavik, 2024 Fidler, 1983 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.11[2.03; 2.20]314,0290%NAVaclavik, 2024 Fidler, 1983 2 Tags Adjustment   - No  - No 2.11[2.03; 2.20]314,0290%NAVaclavik, 2024 Fidler, 1983 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.11[2.03; 2.20]314,0290%NAVaclavik, 2024 Fidler, 1983 2 MatchedMatched 2.54[1.13; 5.71]3150 -NAFidler, 1983 1 All studiesAll studies 2.11[2.03; 2.20]314,0290%NAVaclavik, 2024 Fidler, 1983 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.11[2.03; 2.20]314,0290%NAVaclavik, 2024 Fidler, 1983 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Abalos (Caesarean section (RCT versus no anti ...Abalos (Caesarean section (RCT versus no antihypertensive drugs/placebo)) 0.89[0.59; 1.34]0%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT2 Firoz (Caesarean section (versus Labetalol))Firoz (Caesarean section (versus Labetalol)) 1.18[0.77; 1.80]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Bellos (Cesarean delivery (Randomized control ...Bellos (Cesarean delivery (Randomized controlled trial and Cohort studies)) 0.93[0.64; 1.35]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos (Cesarean delivery (Randomized control ...Bellos (Cesarean delivery (Randomized controlled trial only)) 0.93[0.64; 1.35]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 2.11[2.03; 2.20]0%4,029----Vaclavik, 2024 Fidler, 1983 20.510.01.0